Boston Scientific Corporation

Thanks, Mike. Thanks, Larry. Thinking about 20% growth over a sustained number of years of the LRP as conservative just says something about just how impactful Watchman has been as a therapy and I think will continue to be. As we mentioned earlier with Robbie's question, even the currently indicated population is way underpenetrated, and that's why we aren't very comfortable in that 20% growth. over the long-range plan. But I think, you know, to answer your questions about some of the studies that are coming up, let me talk, you know, about them first closure. So that's trial that is going to be reported on AHA. I don't think it's a particularly good read-through for CHAMP. It's a very different European population, a very different primary endpoint, a shorter follow-up. You know, we continue to think that other trials, like PROG-17 and OPTION, honestly give us, you know, really confidence in what we hope that Champion will show. I think in terms of Olon AF and a trial called Ocean that will be reported out at AHA, you know, both of those, first off, if Ocean is confirmatory of Olon AF, that's great news, right, saying that low-risk patients undergoing AF ablation may no longer need stroke prevention. And I want to, you know, remind you all, right, that up until now, except for very select populations, AF ablation was only really indicated as a way of managing patients with significant symptoms from their AF. And so, this supports the continued growth of FARA pulse as patients seek AF ablation in order to come off their blood thinners. But, and this is important, the patients who are currently getting concomitant FARA watch procedures, are not the low-risk patients who were studied in the loan AF. And we have not seen any material impact to concomitant following the publication of a loan. And again, sort of taking all of this together, you know, the significantly under-penetrated currently indicated population, the prospect of indication expansion with trial-like champion, the continued growth in ablation for AF, We remain really comfortable with the projection of 20% annualized growth over our LRP. All right.

Thank you so much. The next question comes from Rick Wise with Stifel. Please go ahead.

Good morning, Mike. Hi, John. I'd like to focus on the very impressive margin performance. John, you kept saying strong drop through to margins from the revenue outperformance. Got it. But I was hoping you'd sort of give us a little more color. I mean, your gross margins, which I know you don't guide to specifically, almost back now to pre-COVID levels. Help us think through as we try to model looking ahead, where do we go from here on the margin front? How big a driver of your operating margin goals is gross margin. And just help us understand maybe with a little more color the drivers from here. It just feels like, given the revenue strength and what we saw this quarter, that your 50 basis point annual improvement could prove conservative, he said optimistically. Thank you.